How do you prepare health authority interactions with the EMA and FDA that genuinely move the approval process forward?
We prepare and support health authority interactions with the EMA, FDA, BfArM and other agencies: from scientific advice and pre-submission meetings through question framing to inspection and CAPA communication. What matters is not the meeting itself but the question that precedes it. A precise, decision-enabling question determines whether the authority's response is usable; a vague question yields an answer that no one can rely on later in the assessment procedure.
- Pharma
- Biotech
- MedTech
- IVD
Overview
Why does health authority communication fail in the approval process?
Health authority interactions with the EMA, FDA, BfArM, PEI, ANSM, MHRA and Swissmedic · Regulation (EC) No 726/2004, 21 CFR Part 312/314/601, EU 2017/745
Last updated: 2026-06-12
Health authority interactions are critical milestones along the approval pathway. It is not the meeting that determines their value, but the preparation. Four points where communication most often falls flat:
- Vague question framing: an authority such as the EMA answers only the question asked in its scientific advice under Regulation (EC) No 726/2004; an ambiguous question yields no usable answer.
- Wrong procedure or wrong meeting type: pre-IND, end-of-phase-2 and pre-NDA/BLA meetings carry different expectations at the FDA; the legal framework is 21 CFR Part 312 (IND), Part 314 (NDA) and Part 601 (BLA).
- Interaction sought too late: if advice is requested only after the study or CMC design has been fixed, the feedback can no longer be incorporated; trial conduct is governed by the Clinical Trials Regulation (EU) No 536/2014.
- Defensive inspection communication: responses to findings without root cause analysis and without a timed CAPA jeopardise closure; at the FDA this relates to the cGMP requirements under 21 CFR Part 211.
Services
How we support you
Scientific Advice & Pre-Submission Meetings
Briefing document and decision-enabling list of questions for EMA scientific advice under Regulation (EC) No 726/2004 and FDA meetings; translation of the meeting minutes into a prioritised action list.
FDA Meeting Strategy (Pre-IND to NDA/BLA)
Meeting request and question package for pre-IND, end-of-phase-2 and pre-NDA/BLA meetings along 21 CFR Part 312, 314 and 601, with a justified preferred option per question.
National Authorities & Notified Bodies
Initial applications and variations to the BfArM, PEI, ANSM, MHRA and Swissmedic under Directive 2001/83/EC, as well as coordination of national procedures with notified bodies under EU 2017/745 (MDR).
Learn more →Inspection & CAPA Communication
Structured response letters to findings (Form FDA 483, Warning Letter, EU GMP inspection reports), CAPA plan with root cause analysis and supported communication through to regulatory closure.
Briefing Documents & Question Framing
Preparation of the briefing book or meeting request package setting out the company's position on each question, including backgrounders on development strategy, clinical endpoints and CMC.
Communication Training for Health Authority Meetings
Preparation and mock meeting for RA teams and management: precise wording without over-disclosure, a question-and-answer script and composed handling of critical follow-up questions.
How we work together
What it comes down to
Health authority communication rarely fails because of the authority; it fails because of the preparation. Three things have to fall into place in the right order: first the decision you need (an accepted clinical endpoint, a CMC strategy, a study design), then the question that brings about exactly that decision, and only then the procedure, that is, EMA scientific advice under Regulation (EC) No 726/2004 or an FDA meeting within the IND under 21 CFR Part 312. Anyone who reverses the order and books the meeting first ends up framing questions the authority cannot answer in a decision-enabling way, and squanders a slot that cannot be repeated at will.
The real bottleneck is the briefing document and the timing. Scientific advice is not binding but carries significant weight in the assessment procedure; a later deviation must be documented and justified. And advice that arrives only after the study design has been fixed can no longer be incorporated. This is exactly where we come in: we define the decision before the question with you, frame the question before the meeting, and afterwards translate the authority's response into a prioritised action list rather than filing it away as a finished document.
Our approach
Our approach
Step
Result
Objective Definition & Authority Selection
A defined regulatory question, the appropriate authority and procedure type, such as EMA scientific advice or an FDA Type B meeting.
Question Framing
A precise, decision-enabling list of questions aligned with the development stage and the decision to be made.
Briefing Document
A complete briefing book or meeting request package with the company's justified position on each question.
Submission & Preparation
A submitted dossier in the authority's format and a completed mock meeting to prepare the team.
Conduct of the Meeting
A meeting led to a documented authority position (minutes or advice letter).
Follow-Up & Implementation
The authority's response translated into prioritised actions, with every deviation from the advice documented and justified.
Common pitfalls
Where projects commonly fail
The questions are framed too openly or ambiguously.
An authority answers only what was asked; a vague question yields an evasive or unusable answer that no one can rely on later in the assessment procedure.
Scientific advice is mistaken for a binding commitment.
EMA advice under Regulation (EC) No 726/2004 is not legally binding but carries significant weight in the assessment procedure; anyone who deviates from the advice without documented justification should expect objections.
The health authority meeting is scheduled too late.
Anyone who seeks scientific advice or an end-of-phase-2 meeting only after fixing the study design can no longer incorporate the feedback and bears the risk of a rejected endpoint alone.
The briefing document overloads the authority with data instead of a clear position.
Without a justified preferred option per question, the discussion shifts into the meeting itself, where there is no time for genuine clarification.
The response to inspection findings (Form FDA 483, Warning Letter) is handled defensively or without a root cause.
CAPAs without a traceable cause analysis and realistic timelines provoke follow-up requirements instead of closure; data integrity deficiencies must be addressed with reference to 21 CFR Part 11.
FAQ
Frequently asked questions
Sources
- Regulation (EC) No 726/2004 - primary text (EMA, centralised marketing authorisation procedure, scientific advice)
- Directive 2001/83/EC - Community code relating to medicinal products for human use
- Regulation (EU) No 536/2014 - Clinical Trials Regulation (CTR)
- US FDA - 21 CFR Parts 11, 211, 312, 314, 601, 807, 814
- FDA Guidance: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products (meeting types A/B/C)
- FDA Guidance: Requests for Feedback and Meetings for Medical Device Submissions - The Q-Submission Program
- Regulation (EU) 2017/745 (MDR) - primary text
- Writer source file: health-authority-interaction.md (2026-03-29)
- https://theentourage.de/expertise/health-authority-interaction/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Related insights
All insights →Regulations & standards considered
- Regulation (EC) No 726/2004 (EMA, centralised marketing authorisation procedure, scientific advice)
- Directive 2001/83/EC (Community code relating to medicinal products for human use)
- Regulation (EU) No 536/2014 (Clinical Trials Regulation, CTR)
- 21 CFR Part 312 (Investigational New Drug Application, IND)
- 21 CFR Part 314 (New Drug Application, NDA)
- 21 CFR Part 601 (Biologics License Application, BLA)
- 21 CFR Part 211 (cGMP for finished pharmaceuticals)
- 21 CFR Part 11 (electronic records and signatures)
- 21 CFR Part 807 (510(k) Premarket Notification)
- 21 CFR Part 814 (Premarket Approval, PMA)
- EU 2017/745 (MDR)
Related topics
Regulatory Affairs →
Strategic market access beyond the individual health authority interaction
International Market Access →
Coordinating multiple national authorities across parallel procedures
FDA Approval for Medical Devices →
The FDA pathway for medical devices: 510(k), PMA and Q-Submission
MDR Consulting →
Communication with notified bodies and authorities under EU 2017/745
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences